Betaphos, suspension for injection 5 mg/ml + 2 mg/ml

- Betaphos is indicated in the treatment of various rheumatic diseases, dermatological, allergic, collagen diseases and and other conditions responsive to corticosteroids.

-As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in osteoarthritis, rheumatoid arthritis.

-In case of Dermatologic Conditions.

-As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in bursitis under heloma durum or molle, bursitis under calcaneal spur, bursitis over hallux rigidus, bursitis over digiti quinti varus; synovial cyst, Morton’s neuralgia (metatarsalgia); tenosynovitis, periostitis of cuboid.

- Allergic Conditions:

Status asthmaticus, chronic bronchial asthma, seasonal or perennial allergic rhinitis, severe allergic bronchitis, contact dermatitis, atopic dermatitis, hay fever, angioneurotic edema, serum sickness, drug hypersensitivity reactions, insect bites.

- Osteoarthritis, rheumatoid arthritis, bursitis, lumbago, sciatica, coccydynia, acute gouty arthritis, torticollis, ganglion cyst, ankylosing spondylitis, radiculitis, exostosis, fasciitis.

- Atopic dermatitis (nummular eczema); neurodermatitis (circumscribed lichen simplex); contact dermatitis; severe solar dermatitis; urticaria; hypertrophic lichen planus; necrobiosis lipoidica diabeticorum; alopecia areata; discoid lupus erythematosus; psoriasis; keloids; pemphigus; dermatitis herpetiformis; cystic acne.

- During an exacerbation or as maintenance therapy in selected cases of disseminated lupus erythematosus, polyarteritis nodosa, scleroderma and dermatomyositis.

- For palliative management of leukemias and lymphomas in adults; acute leukemia of childhood.

- Adrenogenital syndrome; ulcerative colitis; regional ileitis; sprue; corticosteroid-responsive blood dyscrasias; nephritis, nephrotic syndrome.

- Primary or secondary adrenocortical insufficiency may be treated with Betaphos but should be supplemented with mineralocorticosteroids, if applicable  

Betamethasone is a synthetic glucocorticoid. It has a strong anti-inflammatory, anti-allergic and immunosuppressive activity. The anti-inflammatory, immunosuppressive and anti-allergic properties of glucocorticoids are responsible for most of the therapeutic applications. The main aspects of these properties are as follows: reduction of the immunoactive cells near the inflammation focus; reduced vasodilation; stabilization of the lysosomal membranes; inhibition of phagocytosis; reduced production of prostaglandins and related substances